Preliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors

被引：0
|
作者：
Johnson, M. [1 ]
Galsky, M. [2 ]
Barve, M. [3 ]
Goel, S. [4 ]
Park, H. [5 ]
Du, B. [6 ]
Mu, S. [7 ]
Ramakrishnan, V. [8 ]
Wood, K. [9 ]
Wang, V. [10 ]
Lakhani, N. [11 ]
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[2] Icahn Sch Med Mt Sinai, Hematol & Med Oncol, New York, NY 10029 USA
[3] Mary Crowley Canc Res, Med Oncol, Dallas, TX USA
[4] Montefiore Med Ctr, Med Oncol, 111 E 210th St, Bronx, NY 10467 USA
[5] Washington Univ, Med Oncol, St Louis, MO USA
[6] Beigene USA Inc, Pharmacovigilance & Drug Safety, San Mateo, CA USA
[7] BeiGene USA Inc, Clin Pharmacol, Ft Lee, NJ USA
[8] BeiGene USA Inc, CDx & Biomarker Dev, San Mateo, CA USA
[9] BeiGene USA Inc, Clin Sci, San Mateo, CA USA
[10] BeiGene USA Inc, Biostat, San Mateo, CA USA
[11] START Midwest, Dev Therapeut, Grand Rapids, MI USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
421P
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [41] Preliminary safety and efficacy results of KN046 in combination with KN026 in patients with locally advanced unresectable or metastatic HER2-positive solid cancer
    Gong, Jifang
    Chen, Lei
    Sun, Meili
    Zhang, Yanming
    Ying, Jieer
    Wang, Xiangcai
    Ni, Mingli
    Zhuang, Zhixiang
    Guo, Baohong
    Xiao, Long
    Xia, Summer
    Shen, Lin
    CANCER RESEARCH, 2022, 82 (12)
  • [42] Preliminary Phase 1 Results of the PD-1 Inhibitor ABBV-181 in Japanese vs Western Patients With Advanced Solid Tumors
    Kuboki, Yasutoshi
    Kondo, Shunsuke
    Drew, Rasco
    John, Powderly
    Alexander, Spira
    Jason, J. Luke
    Daniel, Afar
    Stefan, Englert
    Hashiba, Hideyuki
    Stacie, Lambert
    Apurvasena, Parikh
    Shimizu, Eisuke
    Greg, Vosganian
    Doi, Toshihiko
    Yamamoto, Noboru
    ANNALS OF ONCOLOGY, 2019, 30
  • [43] A first-in-human phase 1a dose-escalation study of BGB-15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti-PD-1 antibody) in patients (pts) with advanced solid tumors
    Deva, Sanjeev
    Zhou, Caicun
    Bishnoi, Sarwan K.
    Lau, Peter Kar Han
    Tran, Ben
    Ba, Yi
    Galsky, Matt D.
    Wang, Yongsheng
    Zhang, Yanqiao
    Luo, Suxia
    Chang, Victoria
    Yu, Cunjing
    Zhang, Teresa
    Zhang, Heather
    Ma, Jiafang
    Naicker, Kirsha May
    Yap, Timothy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors.
    Powderly, John
    Shimizu, Toshio
    LoRusso, Patricia
    Razak, Albiruni
    Miller, Kathy
    Balar, Arjun
    Bruix, Jordi
    Michel, Loren
    Blaney, Martha
    Guan, Xiaowen
    Lacy, Susan
    Lally, Satwant
    Lambert, Stacie
    Leibman, Rachel
    Vosganian, Gregory
    Golan, Talia
    Tolcher, Anthony
    CANCER RESEARCH, 2021, 81 (13)
  • [45] A phase I first-in-human study of XL092 in patients (pts) with locally advanced or metastatic solid tumors: Results from dose-escalation of XL092 alone and in combination with atezolizumab
    Sharma, M. R.
    Subbiah, V.
    Shapiro, G.
    Pal, S. K.
    Agarwal, N.
    Wentzel, K.
    Fang, B.
    Zhang, N.
    Schwickart, M.
    Wang, Z.
    Curran, D.
    Patnaik, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S760 - S760
  • [46] A phase 2 multi-arm study of magrolimab in combination with docetaxel in patients with locally advanced or metastatic solid tumors: ELEVATE Lung and UC.
    Subbiah, Vivek
    Vaishampayan, Ulka N.
    Puri, Sonam
    Kummar, Shivaani
    Martinez Perez, Julia
    Italiano, Antoine
    Shao, Jiang
    Bathia, Riya
    Sills, Aoife
    Pravin Patel, Sandip
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] A phase 2, multiarm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors.
    Subbiah, Vivek
    Vaishampayan, Ulka N.
    Puri, Sonam
    Lin, Lanjia
    Chao, Mark
    Ramsingh, Giri
    Kummar, Shivaani
    Strauss, James F.
    Patel, Sandip P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [48] Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 (a PARP1-2 inhibitor) as single-agent and in combination with temozolomide in patients with advanced solid tumors (NCT00920595)
    Campone, Mario
    Plummer, Ruth
    Stephens, Peter
    Brakchi, Zahir
    Aissat-Daudigny, Louiza
    Kasiborski, Fabrice
    Cambois, Anne
    Moachon, Gilbert
    Brown, Peter D.
    Kayitalire, Louis
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors
    Awada, Ahmad
    Campone, Mario
    Varga, Andrea
    Aftimos, Philippe
    Frenel, Jean-Sebastien
    Bahleda, Rastilav
    Gombos, Andrea
    Bourbouloux, Emmanuelle
    Soria, Jean-Charles
    ANTI-CANCER DRUGS, 2016, 27 (04) : 342 - 348
  • [50] Phase 1/2 study of the novel SUMOylation inhibitor TAK-981 in adult patients (pts) with advanced or metastatic solid tumors or relapsed/refractory (RR) hematologic malignancies.
    Dudek, Arkadiusz Z.
    Juric, Dejan
    Dowlati, Afshin
    Seymour, Erlene Kuizon
    Ahnert, Jordi Rodon
    Wang, Bingxia
    Huszar, Dennis
    Berger, Allison J.
    Friedlander, Sharon
    Gomez-Pinillos, Alejandro
    Proscurshim, Igor
    Olszanski, Anthony J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345